Thomas G. Duell

Gauting, BY, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 20 publications

Long-term outcomes and patterns of failure after empiric SBRT for presumed early-stage lung tumors.

Long-term outcomes and patterns of failure after empiric SBRT for presumed early-stage lung tumors.

Journal: Frontiers in oncology

Published: September 14, 2025

Empiric stereotactic body radiotherapy for presumed early-stage lung cancer : Pulmonary function changes, treatment-related toxicity and survival outcome.

Empiric stereotactic body radiotherapy for presumed early-stage lung cancer : Pulmonary function changes, treatment-related toxicity and survival outcome.

Journal: Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]

Published: January 08, 2025

Assessing ChatGPT's Educational Potential in Lung Cancer Radiotherapy From Clinician and Patient Perspectives: Content Quality and Readability Analysis.

Assessing ChatGPT's Educational Potential in Lung Cancer Radiotherapy From Clinician and Patient Perspectives: Content Quality and Readability Analysis.

Journal: JMIR cancer

Published: December 08, 2024

First-site-metastasis pattern in patients with inoperable stage III NSCLC treated with concurrent chemoradiotherapy with or without immune check-point inhibition: a retrospective analysis.

First-site-metastasis pattern in patients with inoperable stage III NSCLC treated with concurrent chemoradiotherapy with or without immune check-point inhibition: a retrospective analysis.

Journal: Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]

Published: May 11, 2023

Concurrent/sequential versus sequential immune checkpoint inhibition in inoperable large stage III non-small cell lung cancer patients treated with chemoradiotherapy: a prospective observational study.

Concurrent/sequential versus sequential immune checkpoint inhibition in inoperable large stage III non-small cell lung cancer patients treated with chemoradiotherapy: a prospective observational study.

Journal: Journal of cancer research and clinical oncology

Published: January 21, 2023

Case report: Immunovirotherapy as a novel add-on treatment in a patient with thoracic NUT carcinoma.

Case report: Immunovirotherapy as a novel add-on treatment in a patient with thoracic NUT carcinoma.

Journal: Frontiers in oncology

Published: July 16, 2022

Treatment patterns and prognosis of patients with inoperable stage III NSCLC after completion of concurrent chemoradiotherapy ± immune checkpoint inhibition: a decade-long single-center historical analysis.

Treatment patterns and prognosis of patients with inoperable stage III NSCLC after completion of concurrent chemoradiotherapy ± immune checkpoint inhibition: a decade-long single-center historical analysis.

Journal: Journal of cancer research and clinical oncology

Published: June 04, 2022

Planning target volume as a predictor of disease progression in inoperable stage III non-small cell lung cancer patients treated with chemoradiotherapy and concurrent and/or sequential immune checkpoint inhibition.

Planning target volume as a predictor of disease progression in inoperable stage III non-small cell lung cancer patients treated with chemoradiotherapy and concurrent and/or sequential immune checkpoint inhibition.

Journal: Investigational new drugs

Published: April 30, 2021

Real-world prospective analysis of treatment patterns in durvalumab maintenance after chemoradiotherapy in unresectable, locally advanced NSCLC patients.

Real-world prospective analysis of treatment patterns in durvalumab maintenance after chemoradiotherapy in unresectable, locally advanced NSCLC patients.

Journal: Investigational new drugs

Published: January 30, 2021

Durvalumab after Chemoradiotherapy for PD-L1 Expressing Inoperable Stage III NSCLC Leads to Significant Improvement of Local-Regional Control and Overall Survival in the Real-World Setting.

Durvalumab after Chemoradiotherapy for PD-L1 Expressing Inoperable Stage III NSCLC Leads to Significant Improvement of Local-Regional Control and Overall Survival in the Real-World Setting.

Journal: Cancers

Published: December 25, 2020

Targeted Natural Killer Cell-Based Adoptive Immunotherapy for the Treatment of Patients with NSCLC after Radiochemotherapy: A Randomized Phase II Clinical Trial.

Targeted Natural Killer Cell-Based Adoptive Immunotherapy for the Treatment of Patients with NSCLC after Radiochemotherapy: A Randomized Phase II Clinical Trial.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: March 27, 2020

VOC pattern recognition of lung cancer: a comparative evaluation of different dog- and eNose-based strategies using different sampling materials.

VOC pattern recognition of lung cancer: a comparative evaluation of different dog- and eNose-based strategies using different sampling materials.

Journal: Acta oncologica (Stockholm, Sweden)

Published: July 18, 2019

Showing 1-12 of 20

Last Updated: 09/26/2026